Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DN62IU
|
|||
| Drug Name |
AG-270
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Lymphoma [ICD-11: 2A80-2A86; ICD-10: C81-C86; ICD-9: 202] | Phase 1 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | ||
| Company |
Agios Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | S-adenosylmethionine synthase type-2 (MAT2A) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cysteine and methionine metabolism | |||
| Metabolic pathways | ||||
| Biosynthesis of amino acids | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03435250) Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss. U.S. National Institutes of Health. | |||
| REF 2 | Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion. J Med Chem. 2021 Apr 22;64(8):4430-4449. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.